Arbutus to present at jefferies london healthcare conference

Warminster, pa., nov. 14, 2024 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), (“arbutus” or the “company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis b virus (chbv) infection, today announced that the company will present at and host one-on-one meetings at the following upcoming investor conference:
ABUS Ratings Summary
ABUS Quant Ranking